China-based clinical stage biopharmaceutical company Denovo Biopharma has secured 300 million yuan ($43 million) in a Series B round funding round backed by Jiuyou Capital, Sangel Capital, Share Capital, Zheshang Industrial Integration, Yuexiu Industrial Fund, Qianzhan Capital and Wenfang Technology Co., Ltd, according to a media statement.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
